Varian Medical Systems, Inc.
Varian Medical Systems, Inc. Articles
Anchored Beacon transponder receives FDA 510(k) clearance
Varian has announced it has received FDA 510(k) clearance for its Calypso Anchored Beacon transponder. Used with a Varian TrueBeam, Edge and Clinac C-series medical linear accelerators, the Calypso system and Anchored Beacon transponder detects even slight movements of a tumour and helps clinicians deliver lung stereotactic body radiotherapy (SBRT) more precisely.
Varian Halcyon system treats first European patient
Varian has announced an 80-year-old male with head & neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven (UZ Leuven) in Belgium. Halcyon is an advanced cancer treatment system that is more comfortable for the patient while delivering ease-of-use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training, and automated treatment.
Halcyon Treatment System receives FDA 510(k) Clearance
Varian Medical Systems has received FDA 510(k) clearance for its Halcyon system, its new device for cancer treatment. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). "We are proud that Halcyon has now received both 510(k) clearance and CE mark," said Kolleen Kennedy, president of Varian's Oncology Systems business.
Treatment platform to answer the global cancer challenge
Varian Medical Systems has introduced the Halcyon system, an entirely new device for cancer treatment. Engineered to revolutionise clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.